Glycolytic Inhibition Alters Anaplastic Thyroid Carcinoma Tumor Metabolism and Improves Response to Conventional Chemotherapy and Radiation

Vlad C. Sandulache1,2, Heath D. Skinner3, Yuan Wang2, Yunyun Chen2, Cristina T. Dodge2, Thomas J. Ow2, James A. Bankson4, Jeffrey N. Myers2, and Stephen Y. Lai2,5

Abstract
Anaplastic thyroid carcinoma (ATC) accounts for more than 50% of thyroid cancer mortality and is generally refractory to conventional treatment. On the basis of recent studies, we hypothesized that ATC metabolism can be targeted to improve response to chemoradiotherapy. Eight established and authenticated ATC cell lines were sequenced at 140 sites contained within 26 commonly mutated genes to identify novel potential therapeutic targets. Cellular proliferation, energy, and reducing potential stores were measured under conditions of specific nutrient deprivation. Tumor metabolism was evaluated using hyperpolarized 13C MRI in a murine orthotopic xenograft model of ATC. Sensitivity to chemotherapeutic agents and radiation (XRT) was assayed using cytotoxicity assays. We identified mutations in BRAF, NRAS, and KIT but failed to identify generalized novel targets for therapeutic intervention. ATC cell lines exhibited a mesenchymal phenotype and generalized dependence on glucose for energy, reducing potential and survival. Glycolytic inhibition using 2-deoxyglucose (2-DG) sensitized ATC cells to conventional chemotherapy and external beam radiation. In vivo, 2-DG induced a transient, but significant reduction in ATC metabolic activity. Generalized dependence of ATC cells on glucose catabolism makes them susceptible to the sensitizing effects of 2-DG for radiation therapy and chemotherapy. Under in vivo conditions, 2-DG can inhibit ATC metabolism. However, the modest magnitude and transient nature of this effect suggest the need for antimetabolic agents with more favorable pharmacodynamics to achieve therapeutic effects. Mol Cancer Ther; 11(6); 1373–80. ©2012 AACR.

Introduction
Anaplastic thyroid carcinoma (ATC) is a rare and aggressive cancer of the thyroid with extremely poor prognosis. Although ATC only comprises 1.7% of all thyroid cancers in the United States, it accounts for more than 50% of thyroid carcinoma-related deaths (1–3). Cellular dedifferentiation, locoregional invasion and distant metastasis are characteristic features of ATC (2). Despite the use of multimodality treatment combining surgery, external beam radiation, and chemotherapy, the median survival rate (5 months) has improved little over the last few decades. Poor outcomes associated with ATC can be attributed in part to tumor cell resistance to both conventional and targeted chemotherapeutic strategies. Treatment failure and high rates of locoregional and distant metastasis make the development of effective chemotherapeutic agents an urgent necessity.

One hallmark of rapidly proliferating tumor cells is the shift from mitochondrial respiration to aerobic glycolysis (Warburg effect; ref. 4). Although aerobic glycolysis is inefficient from an energetic perspective, it can fulfill the biomass requirements associated with rapid proliferation (5). The distinct metabolism of tumor cells makes targeting of metabolic pathways a promising approach for therapeutic interventions. Metabolic agents targeted toward glucose catabolism [2-deoxyglucose (2-DG), lonicidamine, and bromopyruvate], lactate transport (MCT inhibitors), mitochondrial respiration (metformin), and generalized protein synthesis (mTOR inhibitors) have been described, with varied effectiveness in a variety of solid tumors (6–13).
sought to evaluate the metabolic profile of a comprehensive panel of ATC cell lines to determine optimal metabolic targeting strategies aimed at improving the effectiveness of conventional chemotherapeutic agents and external beam radiation. We further assessed the potential of metabolic targeting in vivo using an orthotopic ATC xenograft model and hyperpolarized $^{13}$C MRI.

**Materials and Methods**

### Cells

A total of 8 previously isolated and described ATC cell lines were used for this study. Cell lines were obtained from an established cell bank in the laboratory of Dr. Jeffrey N. Myers (University of Texas MD Anderson Cancer Center, Houston, TX) under approved institutional protocols. All cell lines were tested and authenticated using short-tandem repeat analysis within 6 months of use for the current project (16). Cells were maintained in either RPMI of MEM growth media supplemented with glutamine, pyruvate, penicillin/streptomycin, and 10% FBS. For proliferation and survival experiments, a baseline growth profile was obtained in Dulbecco’s modified Eagle’s medium containing 25 mmol/L D-glucose (GLC), and 4 mmol/L glutamine (GLN) to standardize conditions across cell lines. Cell phenotypes were further established using a combination of bright field imaging (standard growth conditions), immune-fluorescence, and Western blotting for expression of E-cadherin (BD Biosciences) and vimentin (Dako Cytomation). Sequencing analysis of 140 mutational hot spots in 26 genes was carried out as previously described (Supplementary Table S1; ref. 17).

### Chemicals

2-Deoxyglucose and glutamine were purchased from Sigma-Aldrich. D-Glucose was purchased from ICN Biomedical. Cisplatin was obtained from APP Pharmaceuticals.

### Metabolic studies

Intracellular ATP levels and cellular reducing potential were measured as previously described (18, 19). Proliferation and starvation experiments were carried out for 24 to 72 hours in media supplemented with glucose and glutamine. At the end of the experimental period, relative cell number was ascertained using total DNA content as a surrogate for cell number.

### Cytotoxicity studies

Drug and XRT toxicity was assayed using clonogenic assays. ATC cells were irradiated using a high-dose rate $^{125}$Cs unit (4.5 Gy/min) to the indicated dose. Cells were incubated with drugs of interest for 24 hours, allowed to recover for 10 to 14 days, then fixed and stained using a 1% formalin/crystal violet solution. Colonies were counted and surviving fractions were determined based upon the plating efficiency of the nonirradiated control group.

### Orthotopic ATC tumors

Male athymic nude mice (8–12 weeks) were purchased from the National Cancer Institute (Bethesda, MD), maintained in a pathogen-free facility and fed irradiated mouse chow and autoclaved, reverse osmosis-treated water. The animal facility was approved by the American Association for the Accreditation of Laboratory Animal Care and met all current regulations and standards of the U.S. Department of Agriculture, U.S. Department of Health and Human Services, and the NIH. All procedures were approved by the Institutional Animal Care and Use Committee of The University of Texas MD Anderson Cancer Center. U-HTTH83 luciferase expressing cells (2.5 x 10^5 per mouse) were injected into the right thyroid lobe under direct visualization as previously described (20). Control and 2-DG–treated (500 mg/kg administered intraperitoneal) thyroid tumors were imaged at 2 and 24 hours posttreatment. Following completion of imaging experiments, all animals were sacrificed and tumors were harvested for histologic evaluation.

### Preparation of hyperpolarized [1-13C]Pyruvate

An amount of 20 μL of [1-13C]Pyruvic acid (Isotec) doped with 15 mmol/L Ox63 polarizing radical (GE Healthcare) and 1.5 mmol/L ProHance (Bracco) was polarized using a HyperSense dynamic nuclear polarization (DNP) system (Oxford Instruments). The polarizing target was frozen to approximately 1.4 K in a 3.35T magnetic field and irradiated at 94.136 GHz for 45 to 60 minutes (21, 22). Once the solid-state polarization level reached a plateau, the preparation was dissolved in 4 mL of a heated (180°C) solution containing 80 mmol/L NaOH and 50 mmol/L NaCl, then flushed into a vessel from which 200 μL was drawn for injection. The final solution contained 80 mmol/L pyruvate with a nominal pH of 7.6 and temperature of 37°C.

### MRI and dynamic spectroscopy

All hyperpolarized tracer data was acquired at 7T using a Biospec USR7030 system and B-GA12 imaging gradients (Bruker Biospin Corp). Anesthesia was induced and maintained using 0.5% to 5% isoflurane in oxygen. Animals were placed head first and supine on a sliding bed system. A surface coil (20 mm outer diameter) that was tuned for $^{13}$C was placed over the thyroid. Anatomic imaging was done using the $^1$H channel of a dual-tuned, actively decoupled $^1$H/$^{13}$C volume resonator (72 mm ID; Bruker Biospin Corp). Animal positioning was confirmed using a 3-plane fast low-angle shot (FLASH) gradient-echo sequence (TE = 3.6 milliseconds, TR = 100 milliseconds) and the location of the tumor was observed in RARE T2-weighted axial and coronal spin-echo images (TE = 50 milliseconds, TR = 2,500 milliseconds, with echo train length of 8, 4 cm × 3 cm FOV encoded over a 256 × 192 matrix, and 1-mm slice thickness). For $^{13}$C measurements, signal was excited using the $^1$C channel of the dual-tuned resonator and detected using the surface coil. Dynamic spectra were acquired using a slice-selective
pulse-acquire sequence (SW = 5,000 Hz over 2,048 points, 10 degree excitation and 8-mm slice thickness) that was repeated every 2 seconds for 3 minutes beginning just before injection of 200 µL of 80 mmol/L hyperpolarized pyruvate solution via tail vein catheter. Spectra were phase adjusted, and the area of the pyruvate and lactate spectral peaks was integrated to yield a time–intensity curve reflecting the arrival of hyperpolarized pyruvate and its conversion into hyperpolarized lactate. These curves were integrated in time to calculate the total relative amounts of hyperpolarized pyruvate and lactate observed over the course of each experiment, and a normalized measure of lactate was formed by dividing total lactate by the sum of lactate and pyruvate. Animals were also scanned at 4.7T using dedicated 1H anatomic imaging coils (35-mm ID) for better depiction of disease progression.

Results

ATC cell line characterization

Eight previously isolated and described ATC cell lines were used in this study. Genomic screening of 140 mutational hotspots contained within 26 genes (Supplementary Table S1) confirmed previously identified BRAF V600E mutations in 4 cell lines (U-HTH83, U-HTH104, 8505C, and SW1726) and identified nonsynonymous mutations in Kit (D816H; U-HTH7) and N-Ras (Q61R; U-HTH7). With the exception of BRAF, no other common genomic alteration was found that would suggest efficacy of currently available targeted therapeutic strategies.

Anaplastic tumors generally display an aggressive histology with both epithelial and mesenchymal features (23–25). Of the 8 ATC cell lines evaluated here, only 1 (U-HTH83) exhibited an epithelial morphology and high expression of E-cadherin (Fig. 1). The remaining 7 cell lines had variable vimentin expression, no E-cadherin expression, and a mesenchymal morphology. Given the shown link between a mesenchymal phenotype and resistance to conventional chemotherapy, these findings were discouraging from a therapeutic perspective and prompted us to expand our investigation to other aspects of ATC tumor cell biology.

Glucose catabolism is required for ATC cell line proliferation and survival

Under normal growth conditions (glucose and glutamine) U-HTH83 and U-HTH74 exhibited the highest proliferative rates (Fig. 2). Cell proliferation was measured under conditions of glucose or glutamine deprivation to identify the primary metabolic substrate for this tumor type. In the absence of glutamine, cell number at the 72-hour time point decreased by between 8% (U-HTH74) to 56% (C643) compared with the control condition. In the absence of glucose, corresponding decreases were larger and ranged from 24% (SW1736) to 92% (U-HTH74). Glucose, but not glutamine, starvation resulted in cell death between 48 and 72 hours (Supplementary Fig. S1). Together these data strongly suggested that, although glutamine is needed for ATC cell proliferation, glucose is the primary nutrient, at least under in vitro conditions.

ATC energy levels (ATP) and intracellular potential are driven by the extracellular glucose concentration

Tumor cells can limit DNA damage induced by chemotherapeutic agents and XRT through multiple mechanisms including active efflux, protein binding of toxic compounds, and inactivation of reactive oxygen species (ROS). These mechanisms are energy demanding, the former because of ATP requirements of active transport, the latter 2 because of the need for reducing equivalents to regenerate inactivating proteins such as glutathione (11). As illustrated in Fig. 3, ATC intracellular reducing potential is driven by changes in the extracellular glucose concentration, and not by changes in the glutamine concentration. Although these phenomena occur under in vitro conditions, the results suggested that pharmacologic targeting of glycolysis alone could significantly alter ATP intracellular energy stores and reducing potential.

To confirm this hypothesis, we used a competitive inhibitor of glucose, 2-DG, which is taken up through glucose transporters and phosphorylated by hexokinase resulting in a nonmetabolizable derivative. Administration of 2-DG
evaluated the effects of glycolytic inhibition of ATC cell proliferation and survival in the single-agent setting as well as in combination with conventional chemotherapy and XRT.

2-Deoxyglucose potentiates the cytotoxic effects of chemotherapy and XRT

In the single-agent setting, glycolytic inhibition using 2-DG resulted in a cytostatic effect, with IC_{50} values in the single mmol/L range, consistent with our previous experience in other solid tumor types (data not shown; ref. 18). The combination of 2-DG and cisplatin resulted in increased cell cytotoxicity compared with either agent alone (Fig. 4A).

Baseline in vitro radiosensitivity varied dramatically among ATC cell lines tested, with C643 as the least and U-HTH 74 as the most sensitive cell line. The addition of cisplatin or 2-DG potentiated XRT effects with the combination exhibiting an enhanced effect (representative data shown in Fig. 4B). Although the underlying sensitivity of ATC cells to each single agent (2-DG, cisplatin, and XRT) varied, the combination of all or both drugs with XRT resulted universally in significantly greater cell killing effects than either agent alone.

2-DG transiently decreases ATC tumor reducing potential in vivo

Previous studies have shown in vitro 2-DG potentiation of chemotherapy and radiation effects in various solid tumor types (12, 13). These studies however have had to use supraphysiologic doses administered in a continuous manner to achieve modest therapeutic effects. A short plasma half-life has been thought to contribute to the therapeutic limitations of 2-DG. Until now, however,
there has been no report of the dynamic effects of 2-DG on in vivo tumor metabolism. Our in vitro data suggested that 2-DG would significantly affect the intracellular reducing potential of ATC cells. Because the pyruvate–lactate reaction representing the final step in glycolysis is partially driven by the intracellular reducing potential, we used hyperpolarized (HP) 13C MRI (HP-MRI) using labeled pyruvate to evaluate 2-DG effects on tumor metabolism.

ATC xenografts exhibited rapid growth and aggressive locoregional expansion, with envelopment of critical structures including trachea and esophagus (Fig. 5). Deposition of 13C label from the pyruvate into the lactate pool was observed in dynamic spectra as a growth of signal at the resonance corresponding to C1 of lactate following injection of hyperpolarized pyruvate (Supplementary Fig. S2). A small increase in lactate signal was noted across the experimental time period (Fig. 6A), consistent with the measured increase in tumor size. Following administration of 2-DG, the net conversion of hyperpolarized pyruvate into lactate was lower in treated tumors (n = 3) than in control tumors (n = 4) at 2-hour posttreatment (P = 0.0504; Fig. 6B and C). This effect was not observed at 24 hours posttreatment, with lactate signal varying quite significantly in treated tumors at this time point (data not shown). A second measurement at week 2 showed a similar trend (data not shown), although it is important to note that the second measurement was obtained in tumors that were no longer naive to 2-DG exposure.

Discussion
Despite its low prevalence, anaplastic thyroid cancer remains one of the most difficult cancers to treat. The high rate of locoregional invasion and distant metastasis makes advanced disease at time of presentation common and limits therapeutic options. The use of multimodality treatment strategies has failed to substantially improve clinical outcomes to date (2). One explanation for this failure is the presence of extensive microscopic disease at the time of presentation, which fails to be addressed either surgically or with XRT. Novel therapeutic agents must be identified to improve treatment effectiveness and reduce the morbidity and mortality associated with ATC.

Multiple conventional and targeted therapeutic agents have been used in the preclinical setting (cell lines and mouse xenografts) to variable effect (2, 20, 26–28). In clinical studies, conventional agents such as cisplatin or doxorubicin have shown some effect with respect to disease progression but failed to significantly alter overall survival. Targeted agents such as gefitinib and sorafenib have similarly modest effects when combined with XRT and conventional chemotherapy (1–3, 26, 28, 29). We analyzed 26 commonly mutated genes to identify putative
targets for existing molecular agents. With the exception of the BRAF V600E mutation, no other mutational events were common among the 8 cell lines tested. In addition, the majority of cell lines tested exhibited a mesenchymal phenotype known to correlate with resistance to conventional chemotherapeutic agents. In light of these data, we sought to evaluate an alternative strategy that has received increasing attention in recent years: antiglycolytic targeting.

Under in vitro growth conditions, ATC cell lines require both glucose and glutamine for maximal proliferation, but glucose is essential for maintenance of intracellular ATP, reducing equivalents and survival. Inhibition of glucose catabolism using 2-DG decreased energy levels and improved the cytotoxicity of cisplatin and XRT. Other studies have shown that such effects can be reproduced in preclinical animal models, but only using prolonged administration of supraphysiologic doses of 2-DG (6, 12). Because these treatment regimens cannot be used in the patient population, no clinical applications for 2-DG have been identified despite 30 years of investigation.

One major limitation of 2-DG is its presumed poor in vivo pharmacodynamic profile. Extrapolation from plasma kinetic data has suggested that 2-DG effects in vivo are short lasting and preclude persistent metabolic inhibition of tumors (13). To date, it has not been possible to directly measure the magnitude and duration of 2-DG effects on tumor metabolism in vivo. This is largely because the primary metabolic imaging modality currently available, 18fluoro-2-DG-PET is incompatible with 2-DG treatment.

To evaluate the effects of 2-DG on ATC tumor metabolism, we used real-time MRI in the context of an orthotopic xenograft murine model. HP-MRI has been used in recent years to improve disease staging and to guide therapeutic interventions (30). Pyruvate lactate conversion represents the ultimate step of aerobic glycolysis. This reaction is controlled in part by the availability of reducing equivalents. Changes in the rate of conversion indirectly reflect the reducing potential of tumors. This is important for 2 reasons. First, reducing equivalents are essential for cellular energy and biomass production. Second, reducing equivalents are used by cells to neutralize ROS and prevent DNA damage. Because ROS are the primary mechanism by which XRT induces cell death, the reducing potential of tumors is not only important for tumor growth but also essential for tumor radiosensitivity.

Consistent with its in vitro effects, 2-DG administration resulted in a significant decrease in ATC xenograft reducing potential as shown by decreased HP-MRI signal. Importantly however, the magnitude of the decrease was limited (~30%) and short lived (<24 hours). Together, these data showed experimentally for the first time that (i) 2-DG does in fact inhibit solid tumor metabolism, (ii) the magnitude of this inhibition is small, and (iii) its effective duration is limited. In light of these results, there is a clear need for improved chemistry of antiglycolytic agents designed to improve in vivo effective half-life. There exist 2-DG derivatives whose altered chemistry results in increased inhibition of hexokinase activity (7). To address the short in vivo half-life of 2-DG, prodrugs are being described with improved pharmacodynamics (9). It is likely that these developments will advance glycolytic inhibition from an in vitro phenomenon to a clinical reality in the next few years.

On the basis of our initial data, we believe that HP-MRI is a promising method to evaluate the pharmacodynamic profile of next generation antiglycolytic agents. Integration of this imaging platform with real-time capability will be essential to the development of an iterative process of drug design and optimization which combines in vitro biochemical assays with preclinical animal models of disease. Ongoing studies in our laboratory are aimed at establishing the validity of this paradigm in the context of ATC.

![Figure 5. Real-time imaging of ATC xenografts. A, tumor volume data indicating increasing tumor size during the experimental period and B, representative axial (AX) and sagittal (SGT) 4.7T MRI images (B, brain stem/brain; T, tumor). C, representative H&E images of tumor architecture indicating relationship with adjacent structures and invasion (Tr, trachea; E, esophagus; T, tumor; S, submandibular gland).](image-url)
Conclusions

ATC cells possess few targetable biologic pathways and exhibit a mesenchymal phenotype associated with resistance to conventional agents. Generalized dependence on glucose catabolism makes them susceptible to the effects of antiglycolytic agents. To translate the effects observed in vitro however, newer antiglycolytic compounds with increased effective half-life and potency will be required. The use of HP-MRI represents an essential tool for monitoring the in vivo effectiveness of such novel therapeutic agents and can greatly aid in their design and clinical testing in this and other solid tumors.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors’ Contributions

Conception and design: V.C. Sandulache, H.D. Skinner, T.J. Ow, J.A. Bankson, S.Y. Lai
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): V.C. Sandulache, H.D. Skinner, Y. Wang, Y. Chen, T.J. Ow, J.A. Bankson, S.Y. Lai
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): V.C. Sandulache, H.D. Skinner, T.J. Ow, J.A. Bankson, S.Y. Lai
Writing, review, and/or revision of the manuscript: V.C. Sandulache, H.D. Skinner, T.J. Ow, J.A. Bankson, J.N. Myers, S.Y. Lai
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): V.C. Sandulache, C.T. Dodge, J.A. Bankson
Study supervision: J.A. Bankson, J.N. Myers, S.Y. Lai

Acknowledgments

The authors thank Dr. Matthew Merrit, PhD for his review of and suggestions for the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the NIH.

Grant Support

This research is supported in part by the NIH through National Research Service Award Research Training Grant (NCI) T32 CA060374 (V.C. Sandulache), NIH Mentored Career Development Award K08 DE18061 (S.Y. Lai), the NIH Cancer Center Support grant P30 CA016672 (MD Anderson Cancer Center) and the NCI Small Animal Imaging Resource Program U24 CA126577 (MD Anderson Cancer Center).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received January 16, 2012; revised March 23, 2012; accepted March 29, 2012; published OnlineFirst May 9, 2012.
References


Molecular Cancer Therapeutics

Glycolytic Inhibition Alters Anaplastic Thyroid Carcinoma Tumor Metabolism and Improves Response to Conventional Chemotherapy and Radiation


Mol Cancer Ther 2012;11:1373-1380. Published OnlineFirst May 9, 2012.

Updated version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-12-0041

Supplementary Material
Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2012/04/17/1535-7163.MCT-12-0041.DC1

Cited articles
This article cites 29 articles, 12 of which you can access for free at:
http://mct.aacrjournals.org/content/11/6/1373.full#ref-list-1

Citing articles
This article has been cited by 5 HighWire-hosted articles. Access the articles at:
http://mct.aacrjournals.org/content/11/6/1373.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.